Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 Next >
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
From VALNEVA
Via GlobeNewswire
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
From VALNEVA
Via GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
From VALNEVA
Via GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
From VALNEVA
Via GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
From VALNEVA
Via GlobeNewswire
Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Announces Extension of Existing Loan Agreement
From VALNEVA
Via GlobeNewswire
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
From VALNEVA
Via GlobeNewswire
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
From VALNEVA
Via GlobeNewswire
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
From VALNEVA
Via GlobeNewswire
Valneva Announces the Availability of Documentation for its Shareholder Meeting
From VALNEVA
Via GlobeNewswire
Valneva Files for Chikungunya Vaccine Authorization with Health Canada
From VALNEVA
Via GlobeNewswire
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
From VALNEVA
Via GlobeNewswire
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
From VALNEVA
Via GlobeNewswire
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
From VALNEVA
Via GlobeNewswire
FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review
From VALNEVA
Via GlobeNewswire
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance
From VALNEVA
Via GlobeNewswire
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.